Phio Pharma Q3 net loss narrows to $2.8M; first patient dosed in PH-762 Phase 1b trial

Phio Pharmaceuticals Corp.

2023-Q3 EPS reported -$5.03

Q3 net loss $2.8M ($1.14/sh) vs $3.6M ($3.14/sh) in Q3 2022; cash at Sep 30 $8.4M down from $11.8M at Dec 31 2022.
R&D expenses fell 28% YoY to $1.8M; G&A fell 9% to $1.0M.
First patient dosed in U.S. Phase 1b trial of intratumoral PH-762 (anti-PD-1) for skin carcinomas (NCT06014086).
Trial expected to enroll up to 30 patients across 4-6 U.S. sites; neoadjuvant monotherapy with dose escalation.
Company presented preclinical data on PH-894 (BRD4) and CTLA-4-targeting INTASYL at recent conferences.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Phio Pharmaceuticals Corp. reported the quarter ended September 30, 2023 results: net income Net loss was $2.8 million, or $1.14 per share.

Period: the quarter ended September 30, 2023
Net income: Net loss was $2.8 million, or $1.14 per share
Result: reported results

Exact text from the filing

Phio Pharmaceuticals Corp. (the “Company”) reported its financial results for the period ended September 30, 2023.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Phio Pharmaceuticals Corp. filing history →

Source: SEC EDGAR

accession 0001683168-23-007815

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.